v3.25.4
Revenue - Additional information (Details)
€ in Thousands
1 Months Ended 12 Months Ended
Feb. 28, 2023
EUR (€)
Feb. 28, 2023
USD ($)
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2022
USD ($)
shares
Oct. 31, 2021
EUR (€)
Oct. 31, 2021
USD ($)
Sep. 30, 2021
EUR (€)
shares
Sep. 30, 2021
USD ($)
shares
May 31, 2021
Dec. 31, 2025
EUR (€)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Sep. 30, 2021
USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]                            
Deferred income                   € 38,946   € 51,371    
Proceeds from issuing shares                       71,635    
Eli Lilly and Company                            
Disclosure of disaggregation of revenue from contracts with customers [line items]                            
Deferred income                   38,946   € 50,930 € 64,739  
Issue of ordinary shares (in shares) | shares     9,381,586 9,381,586     3,989,976 3,989,976            
Proceeds from issuing shares             € 25,270 $ 30,000,000            
Gross proceeds from issuance of shares     € 14,122 $ 15,000,000                    
Discount on shares issued     € 451 $ 480,000                    
Up-front payment received € 56,412 $ 60,000,000     € 16,849 $ 20,000,000                
Additional consideration to be received if counterparty exercises option to expand partnership | $   $ 50,000,000                        
Number of performance obligations in collaboration agreement             1             1
Eli Lilly and Company | Equity component                            
Disclosure of disaggregation of revenue from contracts with customers [line items]                            
Deferred income             € 2,047             $ 2,429,000
Eli Lilly and Company | Milestone payments                            
Disclosure of disaggregation of revenue from contracts with customers [line items]                            
Milestone payments received                   € 3,922 $ 4,500,000      
Yarrow Biotechnology, Inc                            
Disclosure of disaggregation of revenue from contracts with customers [line items]                            
Proportion of ownership interest in associate                 8.00%